Validated Biomarkers

QF-Pro® is currently validated for various applications and biomarkers, including:

As a versatile platform technology, QF-Pro® can be tailored to any functional protein target of interest. We work closely with clients to design and create novel functional biomarkers in a range of indications. We are constantly working to increase our off-the-shelf repertoire of biomarkers, of which you can find some examples below:

Immune Checkpoints

PD1/PD-L1 interaction state – validated in cell models, ccRCC, NSCLC, melanoma, CRC and tonsil
CTLA4/CD80 interaction state – validated in cell models, NSCLC, CRC-derived lung metastases and tonsil
TIGIT/CD155 interaction state – validated in cell models, NSCLC, melanoma and control tissue (tonsil)
LAG3/MHC II interaction state – validated in NSCLC and control tissue/tonsil
TIM-3/Gal9 interaction state – validated in NSCLC and control tissue/tonsil

Example 1: Interaction of the immune checkpoint TIGIT/CD155 between Jurkat T cells and CHO-K1 cells.

Example 2: Activation state of Akt in clear cell renal cell carcinoma tissue.

Protein Activation States

Protein interaction states

Example 3: Interaction state of HER2/HER3 in clear cell renal cell carcinoma tissue.

In addition to our validated biomarkers - please contact us to see how we can create a new QF-Pro® assay for you.

Partnerships

Want to work with us? Find out about our companion diagnostics (CDx) partnership program and scientific collaborations. We have extensive collaborative networks around the world where we are running QF-Pro®-based studies.

Papers

Read our latest manuscripts to see how QF-Pro® has been used to advance translational and clinical research. Alternatively, our reviews will show you how quantitative functional proteomics can pave the way to more impactful research.